Zhejiang Huahai Pharmaceutical Co., Ltd. (SHA:600521)

SHA:600521 Ratios and Metrics

Market cap in millions CNY. Fiscal year is January - December.

Fiscal Year	Current	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Oct 20, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Market Capitalization	28,538	25,895	21,592	32,429	32,246	49,180
Market Cap Growth	25.12%	19.93%	-33.42%	0.57%	-34.43%	115.47%
Enterprise Value	34,369	31,481	27,591	37,869	35,435	51,438
Last Close Price	19.15	17.66	14.33	21.08	20.79	32.14
PE Ratio	36.00	23.14	26.00	27.77	66.14	52.89
Forward PE	16.65	23.26	23.26	23.26	20.78	90.52
PS Ratio	3.19	2.71	2.60	3.92	4.85	7.58
PB Ratio	2.85	2.87	2.62	4.19	4.76	7.31
P/TBV Ratio	3.30	3.39	3.13	5.06	5.84	8.73
P/FCF Ratio	-	81.09	34.57	-	-	176.29
P/OCF Ratio	22.93	11.92	9.74	26.10	34.36	31.62
PEG Ratio	-	1.29	1.29	1.29	1.29	1.29
EV/Sales Ratio	3.85	3.30	3.32	4.58	5.33	7.93
EV/EBITDA Ratio	16.61	12.54	12.89	16.98	33.74	27.87
EV/EBIT Ratio	30.15	19.38	20.28	24.00	70.52	37.41
EV/FCF Ratio	-58.24	98.59	44.17	-	-	184.39
Debt / Equity Ratio	0.74	0.83	0.83	0.88	0.82	0.60
Debt / EBITDA Ratio	3.60	2.96	3.20	3.01	5.18	2.19
Debt / FCF Ratio	-	23.42	10.98	-	-	14.52
Asset Turnover	0.44	0.49	0.45	0.49	0.47	0.55
Inventory Turnover	1.02	1.09	0.99	1.04	1.05	1.04
Quick Ratio	0.89	0.82	0.74	0.91	0.90	1.39
Current Ratio	1.56	1.42	1.40	1.65	1.61	2.26
Return on Equity (ROE)	7.99%	12.82%	10.22%	16.20%	7.12%	15.91%
Return on Assets (ROA)	3.49%	5.22%	4.63%	5.87%	2.21%	7.25%
Return on Capital (ROIC)	4.28%	6.42%	5.74%	7.35%	2.72%	8.65%
Return on Capital Employed (ROCE)	7.30%	11.40%	10.30%	11.80%	4.50%	13.60%
Earnings Yield	2.73%	4.32%	3.85%	3.60%	1.51%	1.89%
FCF Yield	-2.07%	1.23%	2.89%	-3.31%	-4.64%	0.57%
Dividend Yield	1.30%	1.42%	1.40%	1.14%	0.48%	0.62%
Payout Ratio	58.44%	42.48%	66.95%	27.26%	79.42%	42.25%
Buyback Yield / Dilution	-1.17%	0.52%	0.19%	-1.80%	1.30%	-4.58%
Total Shareholder Return	0.13%	1.94%	1.58%	-0.66%	1.78%	-3.96%

Source: S&P Global Market Intelligence. Standard template. Financial Sources.